Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-10-20
2009-10-06
Yaen, Christopher H (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100
Reexamination Certificate
active
07598225
ABSTRACT:
We have discovered that by using a recombinant viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding prostate-specific antigen (PSA), operably linked to a promoter capable of expression in the host, a specific humoral and cellular immune response to PSA can be generated. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate the immune response, and contacting the host with additional PSA at periodic intervals thereafter. The additional PSA may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional PSA can be added by contacting the host with PSA by a variety of other methods, including in one preferred embodiment adding PSA. The PSA may be formulated with an adjuvant or in a liposomal formulation.
REFERENCES:
patent: 5833975 (1998-11-01), Paoletti et al.
patent: 5925362 (1999-07-01), Spitler et al.
patent: 6165460 (2000-12-01), Schlom et al.
patent: 0 652 014 (1995-05-01), None
patent: 0 725 139 (1996-08-01), None
patent: WO 92/19266 (1992-11-01), None
patent: WO 95/04548 (1995-02-01), None
patent: WO 95 04548 (1995-02-01), None
Fenton RG Journal of National Cancer Insititutes Aug. 18, 1993, 85 (16):1294-302.
Montefiori et al J. Clin. Immunol Nov. 1992 12(6):429-439.
Paoletti et al Ann N Y Acad Sci. Aug. 1993 12;690:292-300.
Hodge et al (Cancer Res. Nov. 1994;54(21):5552-5).
Fields et al (Fundamental Virology 2nd Ed. Raven Press 1991, pp. 953-973.
Fields et al (Fields Virology 3rd Edition vol. 2, Lippincott, Williams, and Wilkins, pp. 2637-2671).
Abulafia et al., Fed Am Soc Exp Bio., J4(7) 1990.
Corman et al., Journal of Urology, 155 (5 suppl.) 1996.
Correlae et al., Proc. Amer. Assoc. Can Res Annual Meeting 37 (0): 488-489 1996.
Hodge et al., International Journal of Cancer, 63(2): 231-237 1995.
Lu et al., Hybridoma 12(4): 381-9 1993.
Ross et al., Biotechnology Therapeutics 4 (3-4): 197-211, 1993.
Johnson et al., J. Virology vol. 68/5; pp. 3145-3153, 1994.
Montefiore et al., J. Clin. Immunology 12/6, pp. 429-439, 1992.
Graham et al., J. Infectious Diseases, vol. 66/2, pp. 244-252, 1992.
Cooney et al., Lancet, vol. 337/8741, pp. 267-272, 1991.
Panicali Dennis L.
Schlom Jeffrey
Leydig , Voit & Mayer, Ltd.
The United States of America as represented by the Department of
Yaen Christopher H
LandOfFree
Generation of immune response to prostate-specific antigen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Generation of immune response to prostate-specific antigen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Generation of immune response to prostate-specific antigen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4123141